linker for activation of T cells family member 2Genealiases: HSPC046 · LAB · NTAL · WBSCR15 · WBSCR5 · WSCR5
Q-omics provides the consensus-scored LAT2 profile across patient tissues and cancer cell-line models. LAT2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LAT2 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, LAT2 RNA expression shows 23,542 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where LAT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LAT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LAT2 survival associations across molecular data types. LAT2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LAT2 RNA expression–survival associations across cancer types. High LAT2 expression shows unfavorable associations in LGG, LAML, KIRC and UVM, but favorable associations in HNSC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LAT2 RNA expression.
This table summarizes LAT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for LAT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LAT2 shows lower tumor expression in LUSC and LUAD and higher tumor expression in KIRC, KIRP, HNSC and THCA. The KIRC box plot shows higher LAT2 RNA expression in tumor versus normal tissue (log2 FC = +2.035, t-test p < 0.001).
This table shows molecular features associated with LAT2 in patient tissues and cancer cell lines. In patient samples, LAT2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LAT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
